Michael A. Santoro

Ethics and the Pharmaceutical Industry (eBook, PDF)

• Format: PDF

Produktbeschreibung

Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Government officials and social critics have questioned whether the multibillion-dollar industry is fulfilling its social responsibilities. This doubt has been fueled by the national debate over drug pricing and affordable healthcare, and internationally by the battles against epidemic diseases, such as AIDS, in the developing world. Debates are raging over how the industry can and should be expected to act. The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, and marketing.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Cambridge University Press
• Erscheinungstermin: 31. Oktober 2005
• Englisch
• ISBN-13: 9780511133992
• Artikelnr.: 38193273

Autorenporträt

Michael A. Santoro is Associate Professor with tenure in the Business Environment Department at Rutgers Business School, where he teaches courses on business ethics, public policy, labor and human rights, law, ethical issues in the pharmaceutical industry, and China business strategy. Professor Santoro holds a PhD in Public Policy from Harvard University and a JD from the New York University School of Law. As a Research Associate at Harvard Business School, he wrote or co-authored nearly 30 case studies and teaching notes on ethical and legal topics such as global protection of intellectual property, insider trading, the Federal Sentencing Guidelines, and the Fair Credit Reporting Act. Professor Santoro has also published numerous journal articles, op-ed articles, and book chapters on these topics in publications such as Foreign Policy, and Human Rights Quarterly. He is the author of Profits and Principles: Global Capitalism and Human Rights in China (2000).

Inhaltsangabe

Charting a sustainable path for the 21st century pharmaceutical industry
Michael A. Santoro; Part I. Profits, Patients' Rights, and Scientific
Progress: The Ethics of Clinical Research Conducted in Private Enterprises:
1. Drug research: between ethical demands and economic constraints Jurgen
Drews; 2. Emerging international norms for clinical testing: good clinical
trial practice Juhana E. Idanpaan-Heikkila and Sev S. Fluss; 3. The
regulatory and ethical challenges of pediatric research M. Dianne Murphy
and Sara F. Goldkind; 4. Including children in research: participation or
exploitation? Robert M. Nelson; 5. Racial and ethnic inclusiveness in
clinical trials Valentine J. Burroughs; 6. The rights of patients to
participate in clinical trials Glenna Crooks; 7. How should government
regulate stem-cell research? Perspectives of a scientist-legislator The
Hon. Rush Holt; Part II. Marketing and the Efficient Utilization of
Healthcare Resources: Ethical and Public Policy Challenges: 8. Ethics and
prescribing: the clinician's perspective Charles L. Bardes; 9.
Direct-to-consumer advertising of prescription drugs: a policy dilemma
Meredith B. Rosenthal and Julie M. Donohue; 10. Regulation of prescription
drug promotion Thomas Abrams; 11. Off-label communications in marketing
prescription drugs Scott D. Danzis; 12. The need for better health
information: advancing the informed patient in Europe Don E. Detmer, Peter
Singleton and Scott C. Ratzan; 13. Who should get access to which drugs? An
ethical template for pharmacy benefits Norman Daniels, James E. Sabin and
J. Russell Teagarden; 14. The application of cost-effectiveness and
cost-benefit analysis to pharmaceuticals Joel Hay; Part III. Patents,
Pricing, and Equal Access: 15. Intellectual property rights, access to
life-enhancing drugs, and corporate moral responsibilities Patricia H.
Werhane and Michael Gorman; 16. A future agenda for government-industry
relations William Weldon; 17. AIDS activism and the pharmaceutical industry
Martin Delaney; 18. The campaign against innovation Sidney Taurel; 19.
Third world perspectives on global pharmaceutical access James Thuo Gathii;
20. The promise of vaccines and the influenza shortage of 2004: public and
private partnerships Gary R. Noble; Part IV. Charting a Sustainable Path
for the 21st Century: 21. Evolving approaches to healthcare challenges
Thomas M. Gorrie; 22. Property rights in crisis: managers and rescue
Nien-he Hsieh; 23. Blurring the lines: public and private partnerships
addressing global health William Foege; 24. Renegotiating the grand
bargain: balancing prices, profits, people, and principles Greg Koski.